SMARCA2 and cancer: Combining epigenetic drugs with previously identified therapeutic vulnerabilities of BRG1-LOF cancers (such as SMARCA2-degraders or inhibitors of Aurora kinase, CDK4/6, oxidative phosphorylation, or others) [23,25,26,27,28,30] will likely yield greater responses and warrants further investigation.